Dejan Juric

39PUBLICATIONS
431CO-AUTHORS
Molecular targetsPacific Peoples theory of change models for healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosisCross-sectional analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jul 02, 2026
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

|Mar 20, 2026
Perceptions of Prognosis and Hope Among Patients With Advanced Cancer at the Time of Enrollment in an Early-Phase Clinical Trial.

Mary C Boulanger, Debra M Lundquist, Andrea Pelletier

|Jan 08, 2026
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

|Oct 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

Dejan Juric, Daniel Anderson, Afshin Dowlati

|May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.

Andreas Varkaris, Keshan Wang, Mannan Nouri

Pageof 7

Frequent Collaborators

10 joint publications

Aditya Bardia

7 joint publications

Ryan B Corcoran

7 joint publications

Steven J Isakoff

6 joint publications

Leif W Ellisen